[EN] A PHENYL TRIAZOLE DERIVATIVE AND ITS USE FOR MODULATING THE GABAA RECEPTOR COMPLEX [FR] DÉRIVÉ DE PHÉNYLE TRIAZOLE ET SON UTILISATION POUR MODULER LE COMPLEXE DU RÉCEPTEUR GABAA
[EN] A PHENYL TRIAZOLE DERIVATIVE AND ITS USE FOR MODULATING THE GABAA RECEPTOR COMPLEX [FR] DÉRIVÉ DE PHÉNYLE TRIAZOLE ET SON UTILISATION POUR MODULER LE COMPLEXE DU RÉCEPTEUR GABAA
The present invention is concerned with novel triazole compounds of formula (I)
wherein A, X, Y, Z, R
1
, R
2
, and R
3
are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of present invention have affinity and selectivity for the GABA A α5 receptor. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
本发明涉及具有以下式(I)的新型三唑化合物,
其中A、X、Y、Z、R1、R2和R3如本文所述,以及其药学上可接受的盐和酯。本发明的活性化合物具有对GABA A α5受体的亲和力和选择性。此外,本发明涉及制备具有式(I)的化合物,包括它们的药物组合物以及它们作为药物的用途。
[EN] TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS<br/>[FR] DÉRIVÉS DE TRIAZOLE ET LEUR UTILISATION POUR DES TROUBLES NEUROLOGIQUES
申请人:HOFFMANN LA ROCHE
公开号:WO2012062687A1
公开(公告)日:2012-05-18
The present invention is concerned with novel triazole compounds of formula (I) wherein A, X, Y, Z, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of present invention have affinity and selectivity for the GABA A α5 receptor. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
本发明涉及一种新型三唑化合物,其化学式为(I),其中A、X、Y、Z、R1、R2和R3如本文所述,以及其药学上可接受的盐和酯。本发明的活性化合物具有对GABA A α5受体的亲和力和选择性。此外,本发明涉及制备化合物(I)的方法,包括它们的药物组合物以及它们作为药物的用途。
Copper(I) Complexes Bearing 1,2-Phenyl-Bridged P<sup>∧</sup>N, P<sup>∧</sup>N<sup>∧</sup>P, and N<sup>∧</sup>P<sup>∧</sup>N Chelate Ligands: Structures and Phosphorescence
作者:Chao Zeng、Nan Wang、Tai Peng、Suning Wang
DOI:10.1021/acs.inorgchem.6b02721
日期:2017.2.6
With the aim to obtain new phosphorescent Cu(I) compounds, several new 1,2-phenyl-bridged P∧N, P∧N∧P, and N∧P∧N chelate ligands were designed and synthesized. These ligands were found to form complexes with Cu(I) ion readily via either solution reactions or solid-state grinding process. The new Cu(I) compounds based on this class of ligands display phosphorescence with emission color ranging from blue
其目的,以获得新的磷光的Cu(I)的化合物,许多新的1,2-二苯基桥接的P ∧ N,P ∧ Ñ ∧ P,和N ∧ P ∧设计并合成Ñ螯合配体。发现这些配体容易通过溶液反应或固态研磨过程与Cu(I)离子形成络合物。基于这类配体的新的Cu(I)化合物显示磷光,发射颜色范围从蓝色到红色。发现配位体的结构和螯合配位体中的N-杂环的性质对Cu(I)化合物的磷光性质具有重大影响。
[EN] NOVEL TRIAZOLE COMPOUNDS III<br/>[FR] NOUVEAUX COMPOSÉS DE TRIAZOLE III
申请人:HOFFMANN LA ROCHE
公开号:WO2012076590A1
公开(公告)日:2012-06-14
The present invention is concerned with novel 1,2,3-triazole-imidazole compounds of formula (I) wherein X, R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of present invention have affinity and selectivity for the GABA A α5 receptor. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
本发明涉及新颖的1,2,3-三唑-咪唑化合物,其化学式为(I),其中X,R1,R2和R3如本文所述,并且其药学上可接受的盐和酯。本发明的活性化合物具有对GABA A α5受体的亲和力和选择性。此外,本发明涉及制备化合物(I)、包含它们的制药组合物以及它们作为药物的用途。
1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS
申请人:Thomas Andrew
公开号:US20120149675A1
公开(公告)日:2012-06-14
The present invention is concerned with novel 1,2,3-triazole-imidazole compounds of formula (I)
wherein X, R
1
, R
2
, and R
3
are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of present invention have affinity and selectivity for the GABA A α5 receptor. Further the present invention provides a method for the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as therapeutic agents.
本发明涉及新型的1,2,3-三氮唑-咪唑化合物,化学式(I),其中X,R1,R2和R3如本文所述,以及其药用盐和酯。本发明的活性化合物对GABA A α5受体具有亲和力和选择性。此外,本发明提供了一种制备化合物(I)的方法,包括它们的药物组合物以及它们作为治疗剂的用途。